ArrayCGH RGCC: Detect genetic disorders for cancer assessment

Cancer screening & detect cancer of unknown primary

The ArrayCGH RGCC test, which stands for Array Comparative Genomic Hybridization, is a cutting-edge tool that detects chromosomal abnormalities in cancer patients. Offering a higher resolution than traditional microscopic methods, it allows for the precise identification of genetic imbalances. This microarray-based test from RGCC is the most advanced method currently available for detecting unbalanced structural and numerical chromosomal abnormalities in cancer cells.

The ArrayCGH RGCC test is especially useful when the origin of the tumor is unconfirmed, such as in cases of cancer of unknown primary (CUP). The blood test helps pinpoint chromosomal abnormalities that can guide clinicians to identify the primary site of the cancer, providing crucial information for accurate diagnosis and treatment planning. Cells from the original cancer, whether breast, prostate, skin, or another type, can break away and travel to other areas of the body. Once these cells settle elsewhere, they can grow and form new tumors, known as secondary cancers or metastases, while the primary tumor site may still be undetected. Finding the primary tumor is crucial to ensure each patient receives the most effective treatment.

How does the ArrayCGH RGCC test work?

The ArrayCGH RGCC test analyzes a blood sample with innovative liquid biopsy methods to detect genetic abnormalities by comparing the patient's DNA with a reference control. This process provides a detailed, personalized chromosomal profile and is part of RGCC’s precision oncology portfolio.

The cancer blood test isolates circulating tumor cells (CTCs) from the blood, extracts their DNA, and uses a microarray-based technique to analyze the genetic characteristics of the cells. The results offer unique insights into the patient's specific cancer profile, supporting more targeted and effective treatment options.

Who should get an ArrayCGH RGCC test?

The ArrayCGH RGCC test is particularly valuable for patients who have detectable circulating tumor cells (CTCs) but have not yet identified the primary tumor site. It helps these patients uncover critical genetic clues that may lead to the accurate identification of the tumor location, assisting in more precise diagnosis and treatment decisions.